MediWound (NASDAQ:MDWD) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a report issued on Wednesday.

Separately, HC Wainwright reiterated a buy rating and issued a $28.00 target price on shares of MediWound in a report on Friday, March 22nd.

MediWound Stock Performance

Shares of NASDAQ:MDWD opened at $17.75 on Wednesday. The company has a market capitalization of $168.48 million, a PE ratio of -23.05 and a beta of 0.81. The stock has a fifty day moving average of $16.27 and a 200-day moving average of $12.62. MediWound has a one year low of $7.10 and a one year high of $19.86.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. The business had revenue of $5.34 million during the quarter, compared to the consensus estimate of $5.33 million. As a group, research analysts forecast that MediWound will post -1.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC boosted its position in MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after acquiring an additional 6,200 shares during the period. Sargent Investment Group LLC lifted its position in shares of MediWound by 7.0% in the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after purchasing an additional 7,125 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of MediWound during the first quarter worth approximately $427,000. Yelin Lapidot Holdings Management Ltd. grew its position in MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 39,348 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after buying an additional 93,705 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.